FDA approval: Tofacitinib

AI Summary

The FDA approved an abbreviated new drug application (ANDA) for a generic tofacitinib formulation (5 mg and 10 mg tablets) sponsored by Zydus Pharmaceuticals, effective 5 June 2026. This approval record documents regulatory authorization only and contains no clinical trial data, efficacy results, or comparative safety information.

Plain-language summary

FDA approval of a generic tofacitinib formulation; this is a regulatory action record documenting market authorization, not a clinical trial or efficacy study.

Reported figures

Quoted from the source exactly as published.

Clinical bottom line

This is a regulatory authorization record for generic tofacitinib. It does not convey new clinical evidence, efficacy, or safety data. Clinicians should refer to the original approved labeling and published clinical trials for information on indication, dosing, efficacy, and safety.

Caveats

• This record contains no clinical trial results, efficacy endpoints, safety data, or comparative information.
• ANDA approval means bioequivalence to a reference product was demonstrated, but bioequivalence data are not reported in this record.
• Approved indication(s), contraindications, dosing guidance, and safety profile are not stated in this regulatory record.
• No information on patient population, sample size, or study design is provided, as this is not a clinical study.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.